Compare AbbVie Inc (ABBV) vs Huntington Ingalls Industries Inc (HII) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

HII trades at $294.10, up 0.89% with a bullish technical signal supported by recent contract wins and strong earnings beats. The company maintains solid fundamentals with a 4.71% net margin and 12.2% ROE, while analyst consensus targets $384.50 representing 31% upside potential. Recent developments include a $418 million Navy contract and expansion in unmanned systems production.

HII presents a compelling investment case with consistent earnings outperformance, robust defense contracts, and attractive valuation metrics. Key risks include defense budget dependencies and execution challenges, but the company's $54 billion backlog and strategic positioning in naval shipbuilding support long-term growth prospects.